Thyrocare Technologies Limited — Investor Meet, 02-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Thyrocare delivered robust Q3 FY26 consolidated revenue of 196 Cr (+18% YoY), with pathology leading at +20%. Normalized consolidated EBITDA margin hit 32% and PAT jumped 47% YoY. The franchisee network grew to a record 10,300, and quality improved significantly, reaching 3.2 complaints per million tests. Management emphasized sustainable mid-teens growth, driven by strategic investments in specialty services like allergies, enhancing their B2B partnership model with a dedicated phlebotomy fleet and strong tech. Future growth will balance investments and stable margins.